XML 17 R33.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Collaborative, Licensing and Other Arrangements (Details) Share data in Millions, except Per Share data, unless otherwise specified | 12 Months Ended | 36 Months Ended |  |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended | 1 Months Ended | 12 Months Ended |  |  | 3 Months Ended |  | 1 Months Ended | 12 Months Ended |  |  |  | 1 Months Ended | 12 Months Ended |  | 1 Months Ended | 3 Months Ended |  | 1 Months Ended | 3 Months Ended |  | 1 Months Ended |  |  | 1 Months Ended | 12 Months Ended |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2012 USD ($) | Dec. 31, 2011 USD ($) | Dec. 31, 2010 USD ($) | Dec. 31, 2012 | Dec. 31, 2003 USD ($) | Dec. 31, 2012 License Arrangement [Member] | Dec. 31, 2011 Servier [Member] Up-front Payment Arrangement [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Dec. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Oct. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2010 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2009 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Sep. 30, 2008 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 3 [Member] USD ($) | Jul. 31, 2006 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 3 [Member] USD ($) | Dec. 31, 2007 Pfizer Inc. [Member] License Arrangement [Member] USD ($) | Jan. 31, 2011 Collaborative Arrangement [Member] Servier [Member] USD ($) | Jan. 31, 2011 Collaborative Arrangement [Member] Servier [Member] EUR (€) | Dec. 31, 2012 Collaborative Arrangement [Member] Servier [Member] USD ($) | Dec. 31, 2011 Collaborative Arrangement [Member] Servier [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Servier [Member] Sales And Development Milestones [Member] USD ($) | Dec. 31, 2010 Collaborative Arrangement [Member] Servier [Member] Up-front Payment Arrangement [Member] USD ($) | Sep. 30, 2010 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] | Dec. 31, 2012 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] Development Milestone [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] Sales Milestone [Member] USD ($) | Feb. 28, 2009 Collaborative Arrangement [Member] Takeda [Member] | Nov. 30, 2006 Collaborative Arrangement [Member] Takeda [Member] | Dec. 31, 2012 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2011 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2010 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Takeda [Member] Development Milestone [Member] USD ($) | Feb. 28, 2009 Collaborative Arrangement [Member] Takeda [Member] Sales Milestone [Member] USD ($) | Nov. 30, 2006 Collaborative Arrangement [Member] Takeda [Member] Sales Milestone [Member] USD ($) | Nov. 30, 2008 Collaborative Arrangement [Member] Novartis [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Novartis [Member] USD ($) | Nov. 30, 2008 Collaborative Arrangement [Member] Novartis [Member] Development Milestone [Member] USD ($) | Sep. 30, 2009 Collaborative Arrangement [Member] Arana Therapeutics Limited [Member] USD ($) | Sep. 30, 2010 Collaborative Arrangement [Member] Arana Therapeutics Limited [Member] USD ($) | Sep. 30, 2009 Collaborative Arrangement [Member] Arana Therapeutics Limited [Member] USD ($) | Sep. 30, 2009 Collaborative Arrangement [Member] Arana Therapeutics Limited [Member] Sales Milestone [Member] USD ($) | Oct. 31, 2009 Collaborative Arrangement [Member] The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member] USD ($) | Dec. 31, 2010 Collaborative Arrangement [Member] The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member] USD ($) | Dec. 31, 2009 Collaborative Arrangement [Member] The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member] USD ($) | Oct. 31, 2009 Collaborative Arrangement [Member] The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member] Sales Milestone [Member] USD ($) | Mar. 31, 2003 Collaborative Arrangement [Member] Genentech, Inc. ("Genentech") [Member] | Oct. 31, 2003 Collaborative Arrangement [Member] Genentech, Inc. ("Genentech") [Member] Convertible Preferred Stock [Member] USD ($) | Oct. 31, 2003 Collaborative Arrangement [Member] Genentech, Inc. ("Genentech") [Member] Common Stock [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Pfizer Inc. [Member] Sales Milestone [Member] USD ($) | Sep. 30, 2006 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] | Apr. 30, 2006 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] | Dec. 31, 2012 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] USD ($) | Dec. 31, 2011 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] USD ($) | Dec. 31, 2010 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] USD ($) | Sep. 30, 2006 Non-arrangement Transactions [Member] AVEO Pharmaceuticals, Inc. ("AVEO") [Member] Sales Milestone [Member] USD ($) | Sep. 30, 2010 Non-arrangement Transactions [Member] UCB Celltech [Member] USD ($) | Dec. 31, 2010 Non-arrangement Transactions [Member] UCB Celltech [Member] USD ($) | Dec. 31, 2011 Non-arrangement Transactions [Member] Pfizer Inc. [Member] Development Milestone [Member] USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period for recognizing deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,500,000 | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total contract amount awarded |  |  |  |  |  |  |  |  |  | 28,000,000 |  |  |  |  | 64,800,000 |  | 16,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000 |  | 6,000,000 |  | 8,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual term |  |  |  |  |  |  |  | 5 years |  |  | 3 years |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 900,000 | 1,400,000 |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of deferred revenue |  |  |  |  |  |  | 14,900,000 | 2,500,000 | 100,000 |  | 6,600,000 | 18,600,000 | 21,200,000 |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000 | 2,000,000 | 3,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future initial research and development expenses to be funded by counterparty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future other expenses to be funded by counterparty (in hundredths) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing and collaboration agreement revenue | 5,727,000 | 17,991,000 | 2,182,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,500,000 | 34,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 | 100,000 | 900,000 |  |  | 4,200,000 |
Future milestone payments, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 470,000,000 |  |  |  |  |  |  |  |  |  |  |  | 3,250,000 | 19,000,000 |  |  | 14,000,000 |  |  |  | 3,000,000 |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payments, repurchase option not exercised, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 810,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fees paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount due upon achievement of milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,500,000 | 15,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payments with each additional future qualifying product candidate development, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,750,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,700,000
Royalty right expiration period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years | 13 years 6 months |  |  |  |  |  |  | 20 years |  |  | 5 years |  |  |  | 15 years |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |
Proceeds from collaborators |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,200,000 |  |  |  | 2,000,000 | 4,000,000 |  |  | 2,000,000 | 6,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduction in debt under restructured agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of ongoing product programs with potential royalty right milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum borrowing capacity under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses funded through loan facility, maximum (in hundredths) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of versions of original AV-299 created |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |
Additional future milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,300,000 |  |  |  |  |  | 6,300,000 |  |  |
Proceeds from sale of royalty interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  |
Eligible share of operating profits and losses (in hundredths) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |
Repayment of loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 29,600,000 |  |  |  |  |  |  |  |  |  |  |
Number of shares of common stock issuable upon conversion (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.3 |  |  |  |  |  |  |  |  |  |
Par value of common shares issuable upon conversion (in dollars per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 116.25 |  |  |  |  |  |  |  |  |  |
Liquidation preference |  |  |  |  | 29,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 29,600,000 |  |  |  |  |  |  |  |  |  |  |
Number of licenses granted, minimum |  |  |  |  |  | 60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from license fees received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of undisclosed product candidates with milestone payments received |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 910 -SubTopic 310 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph c -Article 5 + Details
Name: | us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of potential cash payments that could result from the contingent consideration arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph f -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPayment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 + Details
Name: | us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(f)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph f -Article 4 + Details
Name: | us-gaap_DebtInstrumentDecreaseForgiveness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net addition or reduction in the carrying amount of deferred revenue during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).(Q1)) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenuePeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate carrying amount, as of the balance sheet date, of liabilities not separately disclosed in the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_OtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of the difference between preference in liquidation and the par or stated values of the preferred shares. + References No definition available. + Details
Name: | us-gaap_PreferredStockLiquidationPreferenceValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + References No definition available. + Details
Name: | us-gaap_ProceedsFromIssuanceOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A -Subsection 1 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. + References No definition available. + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 28 -Article 5 + Details
Name: | us-gaap_TemporaryEquityParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of additional potential cash payments that the Company could receive from collaborative arrangements. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationAdditionalPotentialCashPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of domestic operating profits and losses that Company will receive under collaborative agreements. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPercentageOfOperatingProfitAndLossUnderAgreement
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to the maximum future development and sales milestone payments to be received by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of potential cash payments that the Company will receive should the Company not reacquire intangible assets produced as a result of collaborative agreements. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentRightsNotReacquired
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of potential cash payments that the Company could receive from collaborative arrangements for each of the additional future qualifying product candidate developed. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentWithEachAdditionalFutureQualifyingProductCandidateDevelopment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | xoma_ContractualTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. + References No definition available. + Details
Name: | xoma_DebtInstrumentMaximumBorrowingCapacity
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The period over which deferred or unearned revenue is recognized as revenue during the period. + References No definition available. + Details
Name: | xoma_DeferredRevenueRevenueRecognitionPeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty under a collaborative arrangements. + References No definition available. + Details
Name: | xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterpartyUnderCollaborativeArrangement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount paid to a licensor for license fee during the period. + References No definition available. + Details
Name: | xoma_LicenseFeeAmountPaid
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of fixed-dose combination ("FDC") product candidates included in a portfolio of antihypertensive products from Servier. + References No definition available. + Details
Name: | xoma_NumberOfFixedDoseCombinationProductCandidatesIncludedInPortfolioOfAntihypertensiveProductsFromServier
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Maximum number of licenses granted by the Company. + References No definition available. + Details
Name: | xoma_NumberOfLicensesGrantedMinimum
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of ongoing product programs with potential royalty right milestone payments. + References No definition available. + Details
Name: | xoma_NumberOfOngoingProductProgramsWithPotentialRoyaltyRightMilestonePayments
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of undisclosed product candidates relating to which milestone payments received during the period. + References No definition available. + Details
Name: | xoma_NumberOfUndisclosedProductCandidatesWithMilestonePaymentsReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of versions of product created. + References No definition available. + Details
Name: | xoma_NumberOfVersionsOfProductCreated
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of aggregate costs of other expenses not specifically stated that are funded through collaborative arrangements and are not incurred by the Company. + References No definition available. + Details
Name: | xoma_OtherExpenseFundedThroughCollaborativeArrangementPercentage
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from upfront payment under a license and collaboration agreement during the current period. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPaymentReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to royalty right expiration period. + References No definition available. + Details
Name: | xoma_RoyaltyRightExpirationPeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration